S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?
S&P 500   5,061.82
DOW   37,735.11
QQQ   431.06
5 Small-Cap Energy Stocks Surged in Price and Volume on Friday
Novo Nordisk Arms Wegovy to Be a Triple Threat
Vital Farms Rides the Pasture-Raised Egg Trend to the Bank
3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
M&T Bank, Goldman Sachs rise; Salesforce, Tesla fall, Monday, 4/15/2024
Global smartphone shipments climb nearly 8% in 1st quarter as Samsung retakes the lead
When Will the Next Bull Market Be?

Foghorn Therapeutics (FHTX) Earnings Date, Estimates & Call Transcripts

$6.39
-1.03 (-13.88%)
(As of 04/15/2024 ET)

Earnings Summary

Upcoming
Earnings Date
May. 13Estimated
Actual EPS
(Mar. 7)
-$0.57 Beat By $0.22
Consensus EPS
(Mar. 7)
-$0.79
Skip Charts & View Estimated and Actual Earnings Data

FHTX Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

FHTX Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Foghorn Therapeutics Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20241($0.54)($0.54)($0.54)
Q2 20241($0.44)($0.44)($0.44)
Q3 20241($0.47)($0.47)($0.47)
Q4 20242($0.51)($0.51)($0.51)
FY 20245($1.96)($1.96)($1.96)

FHTX Earnings Date and Information

Foghorn Therapeutics last released its quarterly earnings results on March 7th, 2024. The reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.79) by $0.22. The business earned $5.77 million during the quarter, compared to analysts' expectations of $4.91 million. Foghorn Therapeutics has generated ($2.34) earnings per share over the last year (($2.34) diluted earnings per share). Earnings for Foghorn Therapeutics are expected to grow in the coming year, from ($2.05) to ($1.61) per share. Foghorn Therapeutics has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 13th, 2024 based off prior year's report dates.

Foghorn Therapeutics Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/13/2024
Estimated)
------- 
3/7/2024Q4 2023($0.79)($0.57)+$0.22($0.57)$4.91 million$5.77 million
11/2/2023Q3 2023($0.72)($0.34)+$0.38($0.34)$6.20 million$17.48 million
8/4/2023Q2 2023($0.73)($0.70)+$0.03($0.70)$6.65 million$5.60 million
5/8/2023Q1 2023($0.71)($0.73)($0.02)($0.73)$6.09 million$5.31 million
3/9/2023Q4 2022($0.59)($0.69)($0.10)($0.69)$10.12 million$4.18 million
11/8/2022Q3 2022($0.60)($0.62)($0.02)($0.62)$9.58 million$6.63 million
8/9/2022Q2 2022($0.53)($0.66)($0.13)($0.66)$14.38 million$4.49 million
5/9/2022Q1 2022($0.40)($0.65)($0.25)($0.65)$14.40 million$3.92 million
3/10/2022Q4 2021($0.74)($0.77)($0.03)($0.77)$0.33 million$0.71 million
11/9/2021Q3($0.6670)($0.71)($0.0430)($0.71)$0.50 million$0.04 million
8/10/2021Q2 2021($0.63)($0.63)-($0.63)$0.50 million$0.28 million
5/11/2021Q1 2021-($0.62)($0.62)($0.62)-$0.29 million

Foghorn Therapeutics Earnings - Frequently Asked Questions

When is Foghorn Therapeutics's earnings date?

Foghorn Therapeutics has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, May 13th, 2024 based off last year's report dates. Learn more on FHTX's earnings history.

Did Foghorn Therapeutics beat their earnings estimates last quarter?

In the previous quarter, Foghorn Therapeutics (NASDAQ:FHTX) reported ($0.57) earnings per share (EPS) to beat the analysts' consensus estimate of ($0.79) by $0.22. Learn more on analysts' earnings estimate vs. FHTX's actual earnings.

How much revenue does Foghorn Therapeutics generate each year?

Foghorn Therapeutics (NASDAQ:FHTX) has a recorded annual revenue of $34.15 million.

How much profit does Foghorn Therapeutics generate each year?

Foghorn Therapeutics (NASDAQ:FHTX) has a recorded net income of -$98.43 million. FHTX has generated -$2.34 earnings per share over the last four quarters.

What is Foghorn Therapeutics's EPS forecast for next year?

Foghorn Therapeutics's earnings are expected to grow from ($2.05) per share to ($1.61) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:FHTX) was last updated on 4/15/2024 by MarketBeat.com Staff

From Our Partners